SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

AMONDYS 45

SRPT·Sarepta Therapeutics, Inc.
MIXED
Drug Impact Rating7/10
Trial phase
Approved (Accelerated Approval)
Time to market
Already on the market under accelerated approval (since February 2021). The sNDA for traditional approval has a PDUFA goal date around April 2027.
Why 7/10
The next hard, dated catalyst is the FDA's PDUFA decision on the sNDA seeking to convert AMONDYS 45 from accelerated to traditional approval. The sNDA was accepted for filing on June 30, 2026, and with standard review (10 months), the PDUFA goal date is approximately April 2027. This is a major binary event for a drug that drives a substantial portion of Sarepta's revenue, though the company also has other programs (Elevidys, DM1/FSHD pipeline).
Actionable Insight MIXED

Watch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.

Price Chart

Loading chart...

Executive Summary

AMONDYS 45 (casimersen) is an exon-skipping therapy for Duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 45 skipping. It received FDA accelerated approval in February 2021 based on surrogate dystrophin production endpoints. In November 2025, the confirmatory Phase 3 ESSENCE trial failed to meet its primary endpoint, yet Sarepta submitted sNDAs seeking conversion to traditional approval, which the FDA accepted for filing in June 2026. The drug is already on the market and generated significant revenue as part of Sarepta's PMO franchise ($240.3M in Q3 2026). The next major catalyst is the FDA's PDUFA decision on the sNDA, expected around April 2027 under standard review. The outcome is uncertain given the failed confirmatory trial, making this a high-stakes binary event for a drug that drives a large portion of Sarepta's revenue.

How It Works

AMONDYS 45 (casimersen) is an exon-skipping therapy for Duchenne muscular dystrophy (DMD), a genetic disease that causes progressive muscle degeneration. It is a synthetic molecule designed to 'skip over' a specific faulty section (exon 45) of the dystrophin gene during protein production, allowing the body to produce a shortened but still functional version of the dystrophin protein that DMD patients lack. It is administered as a weekly intravenous infusion.

Trial Status

AMONDYS 45 received FDA accelerated approval on February 25, 2021. The confirmatory Phase 3 ESSENCE study (testing both AMONDYS 45 and VYONDYS 53) failed to meet its primary endpoint, announced in November 2025. Despite this, Sarepta submitted sNDAs seeking conversion to traditional approval, which the FDA accepted for filing on June 30, 2026 under standard review.

The Two-Sided Case

▲ Bull Case5
AMONDYS 45 is already approved under accelerated approval (February 2021) and is generating significant revenue as part of Sarepta's PMO franchise, which delivered $240.3M in Q3 2026 net product revenue and drove the company to raise full-year guidance.
The FDA accepted the sNDA for traditional approval despite the ESSENCE trial miss, suggesting regulators see a path forward. Sarepta's management has expressed confidence that there is no risk of losing marketing authorization.
The drug addresses a clear unmet need for Duchenne muscular dystrophy patients with exon 45 skipping-amenable mutations, a defined genetic subset with few treatment options.
Sarepta has a strong cash position of $998.7M as of September 30, 2026, providing runway to support the franchise and pipeline development regardless of the sNDA outcome in the near term.
Institutional investors like BlackRock added to their SRPT positions in Q2 2026 (28.7% increase), and Goldman Sachs added 89.4%, signaling some confidence in the franchise's value.
▼ Bear Case5
The Phase 3 ESSENCE confirmatory trial failed to meet its primary endpoint in November 2025, raising fundamental questions about the drug's efficacy. The FDA accepted the sNDA for review despite this failure, but the odds of conversion to traditional approval are uncertain.
If the FDA denies the sNDA, the drug's accelerated approval could face withdrawal proceedings, threatening a major portion of Sarepta's revenue stream (the PMO franchise generated $240.3M in Q3 2026).
Sarepta faces competitive pressure from Dyne Therapeutics' z-rostudirsen (targeting exon 51), which has a PDUFA date of January 21, 2027 under priority review, potentially eroding the franchise.
SRPT has a high short interest of 21.14% of estimated shares outstanding as of October 15, 2026, reflecting significant bearish sentiment about the company's outlook.
Analyst consensus is mixed: only 12 of 31 analysts rate it Buy/Strong Buy, with a mean price target of $21.64 (21.4% upside from $17.82) and a recommendation key of 'hold'.

Upcoming Catalysts

  • FDA PDUFA decision on sNDA for traditional approval of AMONDYS 45, expected around April 2027
  • Q4 2026 earnings report and 2027 revenue guidance (early 2027)
  • Multiple ascending dose data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD) expected by end of 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report

Sources · 7

Hover a chip for the title
1 morningstar.com2 msn.com3 msn.com4 fiercepharma.com5 biospace.com6 sec.gov7 msn.com